Solopharm has a new CEO

As reported by the press service of Solopharm, Mamuka Mikhelashvili previously worked as a commercial and then executive director of the company. The appointment "is aimed at further strengthening the company's market position in Russia and international markets and operational efficiency," the pharmaceutical manufacturer emphasized in a statement. Mikhelashvili began his professional career as a pharmacist in a pharmacy chain.

According to SPARK-Interfax, from 2017 to 2019, Mamuka Mikhelashvili was the owner and CEO of M-Pharma LLC, whose main activity is indicated as retail sale of medicines in pharmacies. The company was established in May 2017 and liquidated in August 2019.

Oleg Zherebtsov headed Solopharm in the periods 2012–2023 and 2024–2025. In June 2023, he was replaced as CEO for the first time by Pavel Semyanov, who had previously held the position of the company's financial director. At the same time, Zherebtsov became the chairman of the board of directors of Grotex LLC and the head of the Solopharm Group of Companies. In November 2024, the businessman returned to the position of CEO.

Oleg Zherebtsov founded Grotex in 2010, after selling his stake in the Lenta hypermarket chain he founded. In July 2011, construction of a liquid dosage forms plant began in St. Petersburg. In April 2022, Grotex launched a plant for the production of solid dosage forms; the pharmaceutical manufacturer also produces dietary supplements. Since June 2023, the company has been building a plant for the production of hormonal drugs. Investments amount to at least 9.5 billion rubles. Since 2022, the subsidiary Lonofarm has been implementing a project for an enterprise for the production of anesthetics, plasma-substituting and perfusion solutions, and BSS solutions. The volume of investments in production was estimated at 3.8 billion rubles.

Currently, more than 97% of Grotex LLC belongs to the Cypriot Nelovia, according to SPARK-Interfax. The manufacturer's portfolio includes more than 260 drugs in various therapeutic areas. In the company's latest available financial report for 2020, revenue is at the level of 12.6 billion rubles with a net profit of 2.6 billion rubles.

In 2024, Sergey Trifonov, Commercial Director for Retail Sales, left Solopharm, taking up a new position for the pharmaceutical company Promomed, Executive Director. Dmitry Solovov then replaced Trifonov at Solopharm.